Skip to Main Content

Change in Preferred Drug List Status for Glucocorticoids - Inhaled Drug Class Began on May 6, 2025

Date: 05/16/25

Superior HealthPlan would like to remind providers of Organon and Teva Pharmaceuticals, the manufacturers of Asmanex HFA and QVAR RediHaler respectively, have reported back orders due to ongoing distribution and manufacturing delays.

Due to the shortage, the Texas Health and Human Service Commission (HHSC) removed the non-preferred status of the drugs in the table below from the Authorized Generic (AG) fluticasone HFA products on the Preferred Drug List (PDL), became effective May 6, 2025.

Drug Name

National Drug Code (NDC)

FLUTICASONE PROP HFA 44 MCG

66993007896

FLUTICASONE PROP HFA 110 MCG

66993007996

FLUTICASONE PROP HFA 220 MCG

66993008096

These changes allow providers to prescribe the AG fluticasone HFA products without requiring a PDL prior authorization and continue access to necessary asthma control medications for members.

Please Note: This article is an update from the previously posted article: Change in Coverage Status to Generic Fluticasone HFA and QVAR Redihaler Began on December 15, 2023.